Investigational cell cycle inhibitors in clinical trials for bladder cancer

Bibliography

• Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2008(218):12-20
   PubMedGoogle Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13(12):1501-12
   PubMed Web of Science ®Google Scholar
• Macleod KF, Sherry N, Hannon G, p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995;9(8):935-44
   PubMed Web of Science ®Google Scholar
• Jacks T, Weinberg RA. Cell-cycle control and its watchman. Nature 1996;381(6584):643-4
   PubMed Web of Science ®Google Scholar
• Collins K, Jacks T, Pavletich NP. The cell cycle and cancer. Proc Natl Acad Sci USA 1997;94(7):2776-8
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004;18(22):2699-711
   PubMed Web of Science ®Google Scholar
• Krude T, Jackman M, Pines J, Laskey RA. Cyclin/Cdk-dependent initiation of DNA replication in a human cell-free system. Cell 1997;88(1):109-19
   PubMed Web of Science ®Google Scholar
• Hua XH, Newport J. Identification of a preinitiation step in DNA replication that is independent of origin recognition complex and cdc6, but dependent on cdk2. J Cell Biol 1998;140(2):271-81
   PubMed Web of Science ®Google Scholar
• Coverley D, Laman H, Laskey RA. Distinct roles for cyclins E and A during DNA replication complex assembly and activation. Nat Cell Biol 2002;4(7):523-8
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Cancer cell cycles. Science 1996;274(5293):1672-7
   PubMed Web of Science ®Google Scholar
• Grana X, Garriga J, Mayol X. Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth. Oncogene 1998;17(25):3365-83
   PubMed Web of Science ®Google Scholar
• Mayol X, Grana X. pRB, p107 and p130 as transcriptional regulators: role in cell growth and differentiation. Prog Cell Cycle Res 1997;3:157-69
   PubMedGoogle Scholar
• Vairo G, Livingston DM, Ginsberg D. Functional interaction between E2F-4 and p130: evidence for distinct mechanisms underlying growth suppression by different retinoblastoma protein family members. Genes Dev 1995;9(7):869-81
   Google Scholar
• Steinman RA. Cell cycle regulators and hematopoiesis. Oncogene 2002;21(21):3403-13
   PubMed Web of Science ®Google Scholar
• Nigg EA. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays 1995;17(6):471-80
   PubMed Web of Science ®Google Scholar
• Gautier J, Solomon MJ, Booher RN, cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell 1991;67(1):197-211
   PubMed Web of Science ®Google Scholar
• el-Deiry WS, Tokino T, Velculescu VE, WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75(4):817-25
   PubMed Web of Science ®Google Scholar
• Gu Y, Turck CW, Morgan DO. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 1993;366(6456):707-10
   PubMed Web of Science ®Google Scholar
• Harper JW, Adami GR, Wei N, The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75(4):805-16
   PubMed Web of Science ®Google Scholar
• Xiong Y, Hannon GJ, Zhang H, p21 is a universal inhibitor of cyclin kinases. Nature 1993;366(6456):701-4
   PubMed Web of Science ®Google Scholar
• Polyak K, Lee MH, Erdjument-Bromage H, Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78(1):59-66
   PubMed Web of Science ®Google Scholar
• Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78(1):67-74
   PubMed Web of Science ®Google Scholar
• Lee MH, Reynisdottir I, Massague J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9(6):639-49
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Edwards MC, Bai C, p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995;9(6):650-62
   PubMed Web of Science ®Google Scholar
• Kotala V, Uldrijan S, Horky M, Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases. Cell Mol Life Sci 2001;58(9):1333-9
   PubMed Web of Science ®Google Scholar
• Gorospe M, Wang X, Holbrook NJ. Functional role of p21 during the cellular response to stress. Gene Expr 1999;7(4-6):377-85
   PubMed Web of Science ®Google Scholar
• Besson A, Gurian-West M, Chen X, A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression. Genes Dev 2006;20(1):47-64
   PubMed Web of Science ®Google Scholar
• Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996;272(5263):877-80
   PubMed Web of Science ®Google Scholar
• Mitra AP, Datar RH, Cote RJ. Molecular staging of bladder cancer. BJU Int 2005;96(1):7-12
   PubMed Web of Science ®Google Scholar
• Knowles MA. What we could do now: molecular pathology of bladder cancer. Mol Pathol 2001;54(4):215-21
   PubMedGoogle Scholar
• Olumi AF, Tsai YC, Nichols PW, Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 1990;50(21):7081-3
   PubMed Web of Science ®Google Scholar
• Dalbagni G, Presti JC Jr, Reuter VE, Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer. Diagn Mol Pathol 1993;2(1):4-13
   PubMed Web of Science ®Google Scholar
• George B, Datar RH, Wu L, p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol 2007;25(34):5352-8
   PubMed Web of Science ®Google Scholar
• Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 1994;8(15):1750-8
   PubMed Web of Science ®Google Scholar
• LaBaer J, Garrett MD, Stevenson LF, New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997;11(7):847-62
   PubMed Web of Science ®Google Scholar
• Weiss RH, Joo A, Randour C. p21(Waf1/Cip1) is an assembly factor required for platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Biol Chem 2000;275(14):10285-90
   PubMed Web of Science ®Google Scholar
• Nathe TJ, Deou J, Walsh B, Interleukin-1beta inhibits expression of p21(WAF1/CIP1) and p27(KIP1) and enhances proliferation in response to platelet-derived growth factor-BB in smooth muscle cells. Arterioscler Thromb Vasc Biol 2002;22(8):1293-8
   PubMed Web of Science ®Google Scholar
• Mitra AP, Lin H, Datar RH, Cote RJ. Molecular biology of bladder cancer: prognostic and clinical implications. Clin Genitourin Cancer 2006;5(1):67-77
   PubMed Web of Science ®Google Scholar
• Stein JP, Ginsberg DA, Grossfeld GD, Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90(14):1072-9
   PubMed Web of Science ®Google Scholar
• Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993;7(7A):1126-32
   PubMed Web of Science ®Google Scholar
• Simon R, Struckmann K, Schraml P, Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 2002;21(16):2476-83
   PubMed Web of Science ®Google Scholar
• Horowitz JM, Yandell DW, Park SH, Point mutational inactivation of the retinoblastoma antioncogene. Science 1989;243(4893):937-40
   PubMed Web of Science ®Google Scholar
• Takahashi R, Hashimoto T, Xu HJ, The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. Proc Natl Acad Sci USA 1991;88(12):5257-61
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, Wartinger D, Petrylak D, Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992;84(16):1251-6
   PubMed Web of Science ®Google Scholar
• Miyamoto H, Shuin T, Torigoe S, Retinoblastoma gene mutations in primary human bladder cancer. Br J Cancer 1995;71(4):831-5
   PubMed Web of Science ®Google Scholar
• Shariat SF, Tokunaga H, Zhou J, p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004;22(6):1014-24
   PubMed Web of Science ®Google Scholar
• Grossman HB, Liebert M, Antelo M, p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998;4(4):829-34
   PubMed Web of Science ®Google Scholar
• Cote RJ, Dunn MD, Chatterjee SJ, Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58(6):1090-4
   PubMed Web of Science ®Google Scholar
• Tut VM, Braithwaite KL, Angus B, Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br J Cancer 2001;84(2):270-5
   PubMed Web of Science ®Google Scholar
• Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 2006;37(12):1568-76
   PubMed Web of Science ®Google Scholar
• Kamai T, Takagi K, Asami H, Decreasing of p27(Kip1)and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 2001;84(9):1242-51
   PubMed Web of Science ®Google Scholar
• Sgambato A, Migaldi M, Faraglia B, Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 1999;59(13):3245-50
   PubMed Web of Science ®Google Scholar
• Franke KH, Miklosi M, Goebell P, Cyclin-dependent kinase inhibitor P27(KIP1) is expressed preferentially in early stages of urothelial carcinoma. Urology 2000;56(4):689-95
   PubMed Web of Science ®Google Scholar
• Bartoletti R, Cai T, Nesi G, Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. J Surg Res 2007;143(2):422-7
   PubMed Web of Science ®Google Scholar
• Chatterjee SJ, Datar R, Youssefzadeh D, Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004;22(6):1007-13
   PubMed Web of Science ®Google Scholar
• Kuball J, Wen SF, Leissner J, Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 2002;20(4):957-65
   PubMed Web of Science ®Google Scholar
• Pagliaro LC, Keyhani A, Williams D, Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol 2003;21(12):2247-53
   PubMed Web of Science ®Google Scholar
• Pagliaro LC, Keyhani A, Liu B, Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. Urol Oncol 2003;21(6):456-62
   PubMed Web of Science ®Google Scholar
• Fodor I, Timiryasova T, Denes B, Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol 2005;173(2):604-9
   PubMed Web of Science ®Google Scholar
• Wen J, Zhu X, Liu B, Targeting activity of a TCR/IL-2 fusion protein against established tumors. Cancer Immunol Immunother 2008;57(12):1781-94
   PubMed Web of Science ®Google Scholar
• Card KF, Price-Schiavi SA, Liu B, A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity. Cancer Immunol Immunother 2004;53(4):345-57
   PubMed Web of Science ®Google Scholar
• Belmont HJ, Price-Schiavi S, Liu B, Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein. Clin Immunol 2006;121(1):29-39
   PubMed Web of Science ®Google Scholar
• Fishman MN, Thompson JA, Pennock GK, Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res 2011;17(24):7765-75
   PubMed Web of Science ®Google Scholar
• Xu HJ, Zhou Y, Seigne J, Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res 1996;56(10):2245-9
   PubMed Web of Science ®Google Scholar
• Zhang X, Multani AS, Zhou JH, Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells. Cancer Res 2003;63(4):760-5
   PubMed Web of Science ®Google Scholar
• Carlson BA, Dubay MM, Sausville EA, Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56(13):2973-8
   PubMed Web of Science ®Google Scholar
• Losiewicz MD, Carlson BA, Kaur G, Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994;201(2):589-95
   PubMed Web of Science ®Google Scholar
• Byrd JC, Lin TS, Dalton JT, Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007;109(2):399-404
   PubMed Web of Science ®Google Scholar
• Phelps MA, Lin TS, Johnson AJ, Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009;113(12):2637-45
   PubMed Web of Science ®Google Scholar
• Fornier MN, Rathkopf D, Shah M, Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007;13(19):5841-6
   PubMed Web of Science ®Google Scholar
• Burdette-Radoux S, Tozer RG, Lohmann RC, Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 2004;22(3):315-22
   PubMed Web of Science ®Google Scholar
• Grendys EC Jr, Blessing JA, Burger R, Hoffman J. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2005;98(2):249-53
   PubMed Web of Science ®Google Scholar
• Jung CP, Motwani MV, Schwartz GK. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 2001;7(8):2527-36
   PubMed Web of Science ®Google Scholar
• Motwani M, Rizzo C, Sirotnak F, Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2003;2(6):549-55
   PubMed Web of Science ®Google Scholar
• Chien M, Astumian M, Liebowitz D, In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother Pharmacol 1999;44(1):81-7
   PubMed Web of Science ®Google Scholar
• Wirger A, Perabo FG, Burgemeister S, Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Anticancer Res 2005;25(6B):4341-7
   PubMed Web of Science ®Google Scholar
• Dickson MA, Shah MA, Rathkopf D, A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol. Cancer Chemother Pharmacol 2010;66(6):1113-21
   PubMed Web of Science ®Google Scholar